I found a wonderful write up on Coya's niche- Tregs. I pulled off a tricky move to get this enjoy! Tregs Tregs are a specific subset of CD4-positive T cells discovered in 1995 by Prof. Shimon Sakaguchi, who is on Coya's scientific advisory board. They have a heavily regulatory function in maintaining homeostasis, a state of balance needed for the body to function correctly, in the immune system. Their deletion and dysfunction triggers severe inflammation and development of autoimmune diseases. Tregs have strong immunomodulatory properties in different diseases, for example by inhibiting T cell-mediated immune responses against self-antigens, as a protection against autoimmunity. They are also found in the brain, where they regulate immune response directly or through bystander suppression / signaling to brain-resident immune cells such as microglia and astrocytes. The implication of CNS immune dysfunction in a wide array of neurodegenerative diseases is recognized for two reasons: their main function is to nurture and sculpt the brain, but they have been seen to create an inflammatory loop in neurodegenerative diseases which no longer seems to allow them to perform their normal function, leading to neurodegeneration. Treg function in the CNS(Source: Immunology Letters, Brain-resident regulatory T cells and their role in health and disease, A. Liston, J. Dooley, L. Yshii) Total and resting Tregs are significantly decreased and dysfunctional in neurodegenerative diseases such as Alzheimer's and ALS. Coya showed that Treg dysfunction seems to drive neurodegeneration across neurodegenerative diseases. Tregs are reduced in numbers and function in neurodegenerative diseases. More reduction seems associated with more rapid disease progression. Treg dysfunction in ALS(Corporate Presentation) Inflammation and immune function can be regulated by Tregs. For utmost efficacy, someconsiderthat both Treg function should be activated and suppressing T-effector function lowered. Teffs counterbalance Tregs. Coya 301 modulates Tregs and suppresses Teffs. Coya 302 is a further version adding in a macrophage/microglia suppressor. - In ALS, patients who normally progressed 13.2 points over a year's time on a 48-point scale became practically progression free over 48 weeks with Coya 302 treatment. - Coya 302's results stand out The average life expectancy of ALS patients is 2 to 5 years, with 50% dying within 2.5 years after symptoms onset, which shows just how devastating this disease is. Post-treatment with Coya 302, patients' normal ALS progression seemed to return, suggesting treatment efficacy. Coya 302 essentially gave patients who were on a 2-5 year trajectory to death an extra year of no decline. The results also suggest that efficacy could have been continued if treatment would have continued. This article was written by E. Roudasev<--- PROPS. WELL DONE! >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> & that was the tiny bit of news that I caught whiff of yesterday... the trial continues to show survival & it looks like you MUST stay on the drug forever.... BUT HAVE WE FINALLY FOUND AN ALS TRTEATMENT THAT WORKS! AND WHAT HAPPENS WHEN WE START APPLYING THIS TO OTHER AUTO IMMUNE DISEASES....----> ULTIMATE TARGET $24>
QUANTUM WEEK CONTINUES-? $2.07-0.18 (-8.00%)4:00 PM 06/07/23 NYSE | $USD | Pre-Market: $2.37 +0.30 (+14.49%) <-- DAMN MONSTER 8:38 AM
THIS WILL PROBABLY START A TREND- ScoutCam to change name to Odysight.ai SCTC +5.00%Today, 8:16 AM ... AND IN RELATED NEWS DESIGNER BRANDS TO CHANGE NAME TO DESIGNER AI-
-WATCH LIST- A) WKSP Worksport Ltd. $2.58-0.05 (-1.90%)4:00 PM 06/07/23 NASDAQ | $USD | Pre-Market: $2.69 +0.11 (+4.26%) <------- 8:02 AM
THIS SOUNDS LIKE A SMART MOVE-- SOME RUMBLINGS OF MORE SMALL BANK TROUBLES-- Options This Schwab Stock Cash-Secured Put Could Return 29% At An Annualized Rate 10:00 AM ET 06/07/2023 Charles Schwab (SCHW) is starting to recover from the banking crisis that gripped the market earlier in the year. Schwab stock is back above the 21- and 50-day moving averages and they are both starting to turn upward. Rather than buying the stock outright, we could sell a cash secured put to generate some income, or buy the stock for a lower price than it is trading today. A cash-secured put is a slightly less bullish trade than buying the stock. It is considered a neutral to slightly bullish trade. A cash-secured put involves writing an at-the-money or out-of-the-money put option and simultaneously setting aside enough cash to buy the stock. The goal is to either have the put expire worthless and keep the premium or be assigned and acquire the stock below the current price. An Easy Way To Start With Options Selling put options is an easy place for investors to start with options. They are like a covered call and are pretty easy to understand once you know the basics. Traders selling puts should understand that they may be assigned (i.e., forced to buy) 100 shares at the strike price. Let's look at an example using Schwab stock. With the stock closing at 54.61 Tuesday, investors could sell a July put with a strike price of 52.50 for around $1.80. Investors selling this put would receive $180 into their account, which would be theirs to keep. If Schwab falls below 52.50 by July 21, they would be required to buy 100 shares at 52.50. The effective net cost of the position would be 50.70, thanks to the option premium received. That is 7.16% below Tuesday's closing price. Return On Trade Nearly 29% Annualized If the stock stays above 52.50 at expiry, the put expires worthless, leaving the trader with a 3.55% return on capital at risk. That works out to be 28.8% at an annualized rate. The main risk with the trade is similar to outright stock ownership. If the stock falls quickly, the trade will suffer a loss. However, the premium received will help to offset the loss. The maximum loss on the trade would occur if Schwab fell to $0, which would see the trade lose $10,885. But most traders would cut losses long before then. Cash-secured puts are a great way to generate a return on strong stocks, potentially without ever having to take ownership. If the put does get assigned, the investor takes ownership with a reduced cost base and can potentially begin selling covered calls to generate additional income from the position.
AI-Controlled Drone Goes Rogue, Kills Human Operator in USAF Simulated Test An AI-enabled drone killed its human operator in a simulated test conducted by the U.S. Air Force in order to override a possible "no" order stopping it from completing its mission, the USAF's Chief of AI Test and Operations revealed at a recent conference.